Product Highlight - CAMZYOS®

10 Jul 2024
Product Highlight - CAMZYOS®

First Approved Cardiac Myosin Inhibitor that Targets Hypertrophic Cardiomyopathy at the Source1,2

  • >2x achieved symptom control (NYHA class) and improvements in exercise capacity (pVO2) vs placebo2
  • >4x reduction in mean post-exercise LVOT gradient vs placebo2
  • >2x improved NYHA score by ≥1 class vs placebo2
  •  The safety profile was similar to placebo2

References:
1. Camzyos®. Hong Kong Prescribing Information; Sept 2023.
2. Olivotto I, et al. Lancet. 2020; 396 (10253):759-769.
NYHA = New York Heart Association; pVO2 = peak oxygen consumption; LVOT = left ventricular outflow tract

CAMZYOS® and the CAMZYOS Logo are trademarks of MyoKardia, Inc., a Bristol-Myers Squibb company.

3500-HK-2400006 May 2024


BRISTOL-MYERS SQUIBB PHARMA (HK) LTD
Room 3001-3002, 30/F, Windsor House, 311 Gloucester Rd, Causeway Bay, HK
Tel: (+852) 2510 6188 • Fax: (+852) 2510 6199

Related MIMS Drugs